3 participants
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2020-07-16
- Start Date:
- 2017-09-18
- Completion:
- 2019-02-04
Conditions
- HER2/Neu Negative
- Recurrent Inflammatory Breast Carcinoma
- Stage IV Breast Cancer
- Stage IV Inflammatory Breast Carcinoma
Interventions
- BIOLOGICAL
- OTHER